(NP (NP Pentoxifylline/NN) (PP for/IN (NP (NP the/DT treatment/NN) (PP of/IN (NP (NP infection/NN) (PP with/IN (NP human/JJ immunodeficiency/NN virus/NN)))))) ./.)
(S (NP-SBJ-1 (NP Cytokine/NN dysregulation/NN) (PP in/IN (NP (NP (NP human/JJ immunodeficiency/NN virus/NN type/NN 1/CD) (PRN -LRB-/-LRB- (NP HIV-1/NN) -RRB-/-RRB-)) infection/NN))) (VP-COOD (VP has/VBZ (VP been/VBN (VP documented/VBN (NP *-1/-NONE-) (PP in/IN (NP numerous/JJ studies/NNS))))) and/CC (VP has/VBZ (VP been/VBN (VP cited/VBN (NP *-1/-NONE-) (PP as/IN (NP (NP an/DT important/JJ component/NN) (PP in/IN (NP (NP the/DT pathogenesis/NN) (PP of/IN (NP this/DT retroviral/JJ infection/NN)))))))))) ./.)
(S (NP-SBJ-3 (NP Pharmacological/JJ modification/NN) (PP of/IN (NP cytokine/NN dysregulation/NN))) ,/, (ADVP therefore/RB) ,/, (VP has/VBZ (VP been/VBN (VP suggested/VBN (NP *-3/-NONE-) (PP as/IN (NP (NP a/DT therapeutic/JJ modality/NN) (PP for/IN (NP HIV-1/NN infection/NN))))))) ./.)
(S (NP-SBJ (NP Dr./NNP Dezube/NNP) (PP of/IN (NP (NP Beth/NNP Israel/NNP Hospital/NNP) (PRN -LRB-/-LRB- (NP Boston/NNP) -RRB-/-RRB-)))) (ADVP concisely/RB) (VP reviews/VBZ (NP (NP the/DT state/NN) (PP of/IN (NP (NP our/PRP$ knowledge/NN) (PP regarding/VBG (NP (NP the/DT effects/NNS) (PP of/IN (NP pentoxifylline/NN)) (PP on/IN (NP (NP expression/NN) (PP of/IN (NP (NP tumor/NN necrosis/NN factor-alpha/NN) ,/, (NP (NP a/DT cytokine/NN) (VP known/VBN (S (NP-SBJ */-NONE-) (VP-COOD (VP to/TO (VP influence/VB (NP HIV-1/NN replication/NN))) and/CC (VP to/TO (VP play/VB (NP a/DT possible/JJ role/NN) (PP in/IN (NP (NP the/DT clinical/JJ manifestations/NNS) (PP of/IN (NP (NP advanced/JJ infection/NN) (PP with/IN (NP this/DT virus/NN)))))))))))))))))))))) ./.)
(S (NP-SBJ-4 (NP Pentoxifylline/NN) ,/, (NP a/DT trisubstituted/JJ xanthine/NN derivative/NN) ,/,) (VP-COOD (VP has/VBZ (VP been/VBN (VP used/VBN (NP-5 *-4/-NONE-) (S (NP-SBJ *-5/-NONE-) (VP to/TO (VP decrease/VB (NP blood/NN viscosity/NN))))))) and/CC (VP is/VBZ (VP (ADVP reasonably/RB well/RB) tolerated/VBN (NP *-4/-NONE-) (PP by/IN (NP-LGS (NP most/JJS recipients/NNS) (PP of/IN (NP the/DT drug/NN))))))) ./.)
(S (NP-SBJ (NP Results/NNS) (PP of/IN (NP (NP preliminary/JJ studies/NNS) ,/, (SBAR (WHNP-7 (NP many/JJ) (WHPP of/IN (WHNP which/WDT))) (S (NP-SBJ-8 *T*-7/-NONE-) (VP were/VBD (VP conducted/VBN (NP *-8/-NONE-) (PP by/IN (NP-LGS Dr./NNP)))))) Dezube/NNP))) (VP ,/, (SBAR suggest/VBP (S (NP-SBJ (NP that/IN) (PP use/NN (NP of/IN this/DT)) (PP agent/NN (NP (NP in/IN) (PP combination/NN (NP with/IN antiretroviral/JJ))))) (VP compounds/NNS (VP may/MD (ADJP-PRD prove/VB (PP useful/JJ (NP (NP in/IN the/DT) (PP treatment/NN (NP (NP of/IN) (PP patients/NNS (NP with/IN HIV-1/NN)))))))))))) infection/NN)
